Disappointment for Moberg in Phase II onychomycosis trial
This article was originally published in Scrip
Executive Summary
Sweden's Moberg Derma has said there is only a "low probability" that the final results from an ongoing Phase II study investigating MOB-015, its topical treatment for onychomycosis (nail fungus), will be sufficient for out-licensing the project.